Mitochondrial dysfunction in Parkinson's disease - a key disease hallmark with therapeutic potential.

"Declarations Ethics approval and consent to participateN/A Consent for publicationAll authors consented to publish this manuscript. Competing interestsThe authors report no competing interests. WHO received honoraria for educational and scientific presentations at symposia from AbbVie and Stada Pharma unrelated to the work presented in this manuscript. Competing interests The authors report no competing interests. WHO received honoraria for educational and scientific presentations at symposia from AbbVie and Stada Pharma unrelated to the work presented in this manuscript."

"Funding Open Access funding enabled and organized by Projekt DEAL. FFG received grants from the ParkinsonFonds Deutschland/Stichting ParkinsonFonds, the Netherlands, and the von Behring-Röntgen-Stiftung, Germany. WHO is a Hertie-Senior Research Professor, supported by the charitable Hertie Foundation, Frankfurt/Main, Germany. WHO received grants from the MJFF, the DFG (IRTG-GRK 1901), and the ParkinsonFonds Deutschland/Stichting ParkinsonFonds, the Netherlands, outside of this work."